PepGen reports 53.7% mean splicing correction in DM1 patients at 15 mg/kg dose

PepGen Inc.

Mean splicing correction of 53.7% at 15 mg/kg (n=6) by 22-gene panel at Day 28; all 6 patients responded.
PGN-EDODM1 well-tolerated; no serious treatment-related AEs, all mild/moderate, transient, resolved without intervention.
Dose-proportional muscle concentration increase vs 5 mg/kg (12.3%) and 10 mg/kg (29.1%) cohorts.
FREEDOM2 MAD study 5 mg/kg cohort data expected Q1 2026; 10 mg/kg cohort dosing to begin Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.